This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Forbes H. Norris, MD
ALS Research Foundation 2351 Clay St, Suite 416 San Francisco, CA 94115

Arch Neurol. 1994;51(5):447.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Smith¹ reported on improvement in one case of amyotrophic lateral sclerosis (ALS) during administration of the cyclosporin antibiotic, ceftriaxone. The patient relapsed when ceftriaxone treatment was stopped, but failed to improve during a second course of the antibiotic.²

Robberecht³ found no benefit from the administration of ceftriaxone to six patients with ALS.

I also investigated ceftriaxone treatment in recent patients with ALS. All of them met the World Federation of Neurology criteria⁴ for probable or definite ALS. The hospital files were searched for patients with ALS who were admitted from 1989 through 1992 and treated with antibiotics for any reason. There were 11 patients whose treatment for infection, usually aspiration pneumonitis, included full therapeutic doses of a second- or third-generation cephalosporin, which in six cases was ceftriaxone, administered twice in two patients. There was a total of 18 cephalosporin courses in the 11 cases, which all . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?